Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lineage Cell Therapeutics (LCTX) Return on Assets (2016 - 2025)

Historic Return on Assets for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Q3 2025 value amounting to 0.35%.

  • Lineage Cell Therapeutics' Return on Assets fell 1500.0% to 0.35% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.35%, marking a year-over-year decrease of 1500.0%. This contributed to the annual value of 0.17% for FY2024, which is 200.0% up from last year.
  • As of Q3 2025, Lineage Cell Therapeutics' Return on Assets stood at 0.35%, which was down 1500.0% from 0.31% recorded in Q2 2025.
  • Lineage Cell Therapeutics' Return on Assets' 5-year high stood at 0.1% during Q3 2021, with a 5-year trough of 0.36% in Q3 2022.
  • For the 5-year period, Lineage Cell Therapeutics' Return on Assets averaged around 0.23%, with its median value being 0.21% (2023).
  • Its Return on Assets has fluctuated over the past 5 years, first soared by 2900bps in 2021, then crashed by -2600bps in 2022.
  • Quarter analysis of 5 years shows Lineage Cell Therapeutics' Return on Assets stood at 0.28% in 2021, then grew by 25bps to 0.21% in 2022, then decreased by 0bps to 0.21% in 2023, then rose by 15bps to 0.18% in 2024, then plummeted by -100bps to 0.35% in 2025.
  • Its last three reported values are 0.35% in Q3 2025, 0.31% for Q2 2025, and 0.16% during Q1 2025.